Aidoc vs Qure AI (2026)
Two enterprise imaging AI companies built for different health systems, which is the useful way to read this pair. Aidoc is built for the well resourced hospital: an operating system handling normalisation, continuous performance monitoring and governance across many models, with a January 2026 clearance covering a double digit set of acute indications from one named foundation model and regulator reviewed performance behind it. Qure holds the broadest chest radiograph regulatory footprint in the market across nine products spanning radiography and computed tomography, and its deployments run where radiologist capacity is thinnest, including public health screening programmes. The comparison is not really about accuracy. It is about what the AI is compensating for. Aidoc reorders a worklist that a radiologist will read anyway. Qure is frequently the only read a patient will get, and those are different products with different consequences for a false negative.
- The infrastructure is the durable asset: normalisation, continuous performance monitoring and governance built into the platform so a health system can run many models without re architecting per algorithm.
- The January 2026 clearance covers a double digit set of acute indications from a single named foundation model, with performance figures from a regulator reviewed pivotal study rather than a vendor benchmark.
- The data handling model is published in unusual detail, with de identification performed before upload, which answers the privacy question architecturally rather than in a contract.
- The regulatory footprint across chest radiography is the broadest in the market, spanning nine products, with device dossiers published in the detail that European and other regulators require.
- It is built to work where radiologist capacity is scarce, including screening programmes in resource limited settings, which is a materially different deployment than a United States hospital worklist.
- On premise installation is supported and stated, which removes the data transfer question rather than governing it, and its cybersecurity documentation is reviewed inside its regulatory submissions rather than only by a commercial auditor.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Aidoc and Qure AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Aidoc its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against Qure AI, Aidoc grades higher on several axes, including Autonomy and Oversight Model, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Qure AI its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Set against Aidoc, Qure AI does not grade higher on any scored axis, though the two are level on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Aidoc or Qure AI?
The AI Health Index grades Aidoc higher than Qure AI on every axis that separates them, several axes, including Autonomy and Oversight Model, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Qure AI does not grade higher on any scored axis.
Where do Aidoc and Qure AI differ most?
The widest separation the AI Health Index records between Aidoc and Qure AI is on Model Supply Chain Disclosure, where Aidoc grades A and Qure AI grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Aidoc and Qure AI grade the same?
The AI Health Index grades Aidoc and Qure AI the same on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The two records illustrate the non United States imaging pattern this index tracks: Qure publishes complete device regulatory dossiers and comparatively little United States health privacy or infosec material, because regulatory effort follows market access while privacy expectations are handled in contract.
A United States buyer should therefore ask Qure for the commercial assurance artifacts and a global buyer should ask Aidoc for the device dossiers, and each will find the other vendor stronger on their own axis. Neither publishes pricing. Prevalence also matters more here than either vendor says: identical sensitivity and specificity produce very different false positive burdens in a screening population than in an acute hospital one.